Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124 USD | +0.75% | +1.97% | +28.56% |
Financials (USD)
Sales 2024 * | 1.82B | Sales 2025 * | 2.95B | Capitalization | 11.64B |
---|---|---|---|---|---|
Net income 2024 * | 222M | Net income 2025 * | 1.08B | EV / Sales 2024 * | 5.69 x |
Net cash position 2024 * | 1.27B | Net cash position 2025 * | 2.39B | EV / Sales 2025 * | 3.14 x |
P/E ratio 2024 * |
49.1
x | P/E ratio 2025 * |
11
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.21% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | +0.75% | ||
1 week | +1.97% | ||
Current month | -3.07% | ||
1 month | -7.90% | ||
3 months | +31.98% | ||
6 months | +5.01% | ||
Current year | +28.56% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 124 | +0.75% | 523,125 |
24-03-15 | 123 | -0.57% | 1,245,799 |
24-03-14 | 123.8 | +1.48% | 644,210 |
24-03-13 | 122 | -0.03% | 684,537 |
24-03-12 | 122 | +0.35% | 732,440 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.56% | 11.64B | |
+1.10% | 106B | |
+9.29% | 103B | |
-3.00% | 21.44B | |
-11.89% | 22.11B | |
-26.59% | 20.99B | |
-5.20% | 19.44B | |
-6.58% | 17.6B | |
+5.83% | 13.88B | |
+7.46% | 11.75B |